
Kapil Cotex Ltd Stock Hits 52-Week Low Amid Continued Downtrend
2026-02-24 15:40:08Kapil Cotex Ltd, a player in the Garments & Apparels sector, recorded a fresh 52-week low of Rs.116.45 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial and operational metrics.
Read full news article
Kapil Cotex Ltd Stock Falls to 52-Week Low of Rs.126.45
2026-02-23 09:42:14Kapil Cotex Ltd, a player in the Garments & Apparels sector, has recorded a fresh 52-week low of Rs.126.45 today, marking a significant decline amid persistent downward momentum. The stock’s recent performance reflects ongoing pressures that have weighed on its valuation and market standing.
Read full news article
Skybiotech Healthcare Q3 FY26: Mounting Losses Signal Deepening Operational Crisis
2026-02-16 14:22:02Skybiotech Healthcare Limited reported a net loss of ₹0.48 crores for Q3 FY26 (Oct-Dec'25), marking a sequential deterioration of 54.84% from Q2 FY26's loss of ₹0.31 crores. The micro-cap garments and apparels company, with a market capitalisation of just ₹27.00 crores, continues to struggle with operational inefficiencies as revenue collapsed 50.00% quarter-on-quarter to ₹0.96 crores. The stock traded at ₹144.90 on February 16, 2026, down 35.54% over the past year, reflecting persistent investor concerns about the company's viability.
Read full news articleAre Kapil Cotex Ltd latest results good or bad?
2026-02-14 19:58:19Kapil Cotex Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a net loss of ₹0.31 crores, which marks a substantial deterioration compared to the previous quarter. Revenue for the quarter stood at ₹1.92 crores, reflecting a quarter-on-quarter decline of 19.67%, although it did show a year-on-year growth of 20.00% compared to the same quarter last year. This inconsistency in revenue generation highlights the company's struggle to maintain stable business momentum. The operating margin has shifted dramatically into negative territory at -11.46%, down from a positive margin of 3.35% in the prior quarter, indicating severe operational inefficiencies. The profit after tax (PAT) margin also fell to -16.15%, further emphasizing the company's profitability issues. The company has been facing difficulties in its core textile operations, leading to a pivot to...
Read full news article
Kapil Cotex Ltd is Rated Strong Sell
2026-02-12 10:10:26Kapil Cotex Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 December 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 12 February 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Kapil Cotex Ltd is Rated Strong Sell
2025-12-28 10:10:03Kapil Cotex Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 December 2025, providing investors with the most up-to-date view of the company's performance and outlook.
Read full news articleResult- Financial Result For Quarter Ended On December 31St 2025
14-Feb-2026 | Source : BSESubmission of Un-Audited Financial Results for the Quarter ended on 31st December 2025
Board Meeting Outcome for Outcome Of Board Meeting To Considered And Approved Un-Audited Financials For The Quarter Ended On 31St December 2025
14-Feb-2026 | Source : BSEOutcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On 31St December 2025
11-Feb-2026 | Source : BSESkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Approval of Unaudited Financial Results for the Quarter ended on 31st December 2025
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available






